Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High‐Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE)
暂无分享,去创建一个
G. Jenkins | J. Baxter | J. Cronin | James Cronin | Elizabeth McAdam | Antonios Danikas | Chris Tselepis | Paul Griffiths | John Baxter | Linzi Thomas | James Manson | Gareth Jenkins | Antonios Danikas | C. Tselepis | L. Thomas | E. McAdam | P. Griffiths | L. Thomas | J. Manson
[1] P. Hainaut,et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. , 2005, Cancer letters.
[2] H. Sasano,et al. Immunohistochemical Studies on EGF Family Growth Factors in Normal and Ulcerated Human Gastric Mucosa , 1997, Digestive Diseases and Sciences.
[3] N. Shaheen,et al. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Gary Longton,et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.
[5] T. Junginger,et al. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis , 1998, Cancer.
[6] D. Wakelin,et al. Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.
[7] C. Reed,et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. , 2001, The Annals of thoracic surgery.
[8] Kenneth K Wang,et al. Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia–Dysplasia–Adenocarcinoma Sequence of Barrett's Esophagus , 2008, Cancer Epidemiology Biomarkers & Prevention.
[9] R. Sandler,et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.
[10] P. V. van Diest,et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas , 2006, Journal of Clinical Pathology.
[11] N. Quenville,et al. Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67 , 1992, Journal of surgical oncology.
[12] Joseph Schlessinger,et al. Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor , 2002, Cell.
[13] H. Smart,et al. Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.
[14] J. Black,et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma , 2004, Journal of Gastrointestinal Surgery.
[15] Janusz Jankowski,et al. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas , 2006, Clinical Cancer Research.
[16] Tsung-Teh Wu,et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] N. Sergina,et al. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. , 2007, Trends in molecular medicine.
[18] H. Ludwig,et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.
[19] P. Altevogt,et al. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease‐dependent ectodomain shedding and exosome secretion , 2008, Journal of cellular biochemistry.
[20] N. Shepherd,et al. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. , 1995, Journal of clinical pathology.
[21] Markus F Neurath,et al. Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy , 2010, Gut.
[22] J. Reynolds,et al. NF-&kgr;B Activation in Esophageal Adenocarcinoma: Relationship to Barrett's Metaplasia, Survival, and Response to Neoadjuvant Chemoradiotherapy , 2004, Annals of surgery.
[23] N. Shepherd,et al. c-erbB2 overexpression in the dysplasia / carcinoma sequence of Barrett ' s oesophagus , 2022 .
[24] D. Beer,et al. Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.
[25] R. Cade,et al. Oesophagectomy for early adenocarcinoma and dysplasia arising in Barrett's oesophagus , 2003, ANZ journal of surgery.
[26] M. Omary,et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.
[27] D. Forman,et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[28] G. Tytgat,et al. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma , 1998, Gut.
[29] J. Ajani,et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas , 2007, Cancer.
[30] Patricia L. Blount,et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .
[31] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[32] J. Black,et al. Epidermal Growth Factor Receptor-Directed Therapy in Esophageal Cancer , 2008, Oncology.
[33] D. Forman,et al. TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort , 2006, Gut.
[34] J R Siewert,et al. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. , 2000, The American journal of pathology.
[35] Edward L. Lee,et al. In situ hybridization for the detection of telomerase RNA in the progression from barrett's esophagus to esophageal adenocarcinoma , 1998, Cancer.
[36] W. Hop,et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. , 2008, American journal of clinical pathology.
[37] D. Ferry,et al. A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response , 2007, Clinical Cancer Research.
[38] G. Lyratzopoulos,et al. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. , 2009, Gastroenterology.
[39] R. Langer,et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study , 2006, Journal of Clinical Pathology.
[40] P. Groeneveld,et al. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.